Subscribe
marianvejcik-istockphoto-com-gavel-uk-
27 October 2017Big Pharma

Teva suffers defeat as Copaxone claims invalidated

The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers